ClinicalTrials.gg
CompletedNCT02001623Updated Dec 29, 2021Results posted

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

A Phase 1/2 interventional study of Tisotumab Vedotin (HuMax-TF-ADC) in Ovary Cancer, Cervix Cancer and Endometrium Cancer, sponsored by Seagen Inc.. Completed at 29 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-29.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
195
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Ovarian Neoplasms by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Ovarian Neoplasms · Pfizer.

Enrollment
6th of 38
195 · median 52
Started
2013
with 2 others
Phase 1/2
4 of 38
none open now
Registered
6th of 38
by date

Among the 38 studies in Ovarian Neoplasms by Pfizer, this one is the 6th largest by enrollment, is one of 3 that started in 2013, is one of 4 in phase 1/2, and was the 6th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 38 studies in Ovarian Neoplasms by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Ovarian Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.

Read the detailed description

The study is conducted in two parts. The dose escalation portion of the trial subjects are enrolled into cohorts at increasing dose levels of HuMax-TF-ADC in 21 day treatment cycles.

In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose of HuMax-TF-ADC as determined in Part 1

03

Conditions studied

  • Ovary Cancer
  • Cervix Cancer
  • Endometrium Cancer
  • Bladder Cancer
  • Prostate Cancer (CRPC)
  • Esophagus Cancer
  • Lung Cancer(NSCLC)
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Keywords

  • ovary cancer
  • cervix cancer
  • endometrium cancer
  • bladder cancer
  • prostate cancer (CRPC)
  • esophagus cancer
  • lung cancer(NSCLC)
  • Squamous cell carcinoma of the head and neck (SCCHN)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with , advanced and/or cancer who have failed available standard treatments or who are not candidates for standard therapy.

Patients must have

  • Age ≥ 18 years.
  • Acceptable renal function
  • Acceptable liver function
  • Acceptable hematological status (without hematologic support
  • Acceptable coagulation status
  • Have an (ECOG) performance status of 0 or 1.
  • of at least three months.
  • A negative serum pregnancy test (if female and aged between 18-55 years old).
  • Women who are pregnant or breast feeding are not to be included.
  • Patients, both females and males, of must agree to use adequate during and for six months after the last infusion of HuMax-TF-ADC.
  • Following receipt of verbal and written information about the study, patients must provide signed before any study-related activity is carried out.

Exclusion criteria

Exclusion Criteria:

  • Known past or current coagulation defects.
  • Ongoing major bleeding,
  • Have cardiac disease
  • A baseline as corrected by Fridericia's formula (QTcF) > 450 msec, a complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left bundle branch block form) or an incomplete left bundle branch block.
  • Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support within one week or pegylated G-CSF within two weeks before the Screening Visit.
  • Have received a cumulative dose of ≥ 100 mg (prednisone or equivalent doses of corticosteroids) within two weeks before the first infusion.
  • Major surgery within six weeks or open within 14 days before drug infusion.
  • Plan for any major surgery during treatment period.
  • Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke.
  • Any anticancer therapy including; small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug within four weeks or five half lives, whichever is longest, before first infusion.
  • Prior treatment with bevacizumab within twelve weeks before the first infusion.
  • Radiotherapy within 28 days prior to first dose.
  • Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.
  • Known past or current other than inclusion diagnosis, except for:
  • Cervical carcinoma of Stage 1B or less.
  • Non-invasive basal cell or squamous cell skin carcinoma.
  • Non-invasive, superficial bladder cancer.
  • Prostate cancer with a current PSA level \< 0.1 ng/mL.
  • Any curable cancer with a complete response (CR) of > 5 years duration.
  • Known seropositivity.
  • Positive serology (unless due to vaccination or passive immunization due to Ig therapy) for
  • Positive serology for based on test at screening.
  • Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.
  • Inflammatory lung disease including moderate and severe asthma and (COPD) requiring chronic medical therapy.
  • Ongoing acute or chronic inflammatory skin disease.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    Tisotumab Vedotin (HuMax-TF-ADC)

    All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)

    Drug: Tisotumab Vedotin (HuMax-TF-ADC)

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events

    Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

    Time frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.

  2. Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events

    Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

    Time frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.

Secondary outcomes

  1. Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Hematology Values

    Number of participants with markedly abnormal hematology values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 hematology value. A markedly abnormal hematology value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  2. Dose Escalation and Expansion Parts: Number of Participants With Markedly Abnormal Coagulation Values

    Number of participants with markedly abnormal coagulation values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 coagulation value. A markedly abnormal coagulation value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  3. Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Biochemistry Values

    Number of participants with markedly abnormal biochemistry results were defined as all participants who experienced at least 1 CTCAE grade \>= 3 biochemistry value. A markedly abnormal biochemistry value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  4. Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  5. Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event of Special Interest

    Bleeding adverse events of special interest included treatment emergent adverse events with preferred terms within the following standardised MedDRA queries (SMQs): Haemorrhage terms, excluding laboratory terms SMQ \[20000039\] (Broad) and Haemorrhage, laboratory terms SMQ \[20000040\] (Narrow). Bleeding adverse events of special interest were evaluated according to the NCI-CTCAE version 4.03. Bleeding events of all grades are included. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  6. Dose Escalation and Expansion Part: Number of Participants Who Experienced a Peripheral Neuropathy Event

    Peripheral neuropathy events of special interest were evaluated according to the NCI-CTCAE version 4.03. Peripheral neuropathy events of all grades are included in the numbers below. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  7. Dose Escalation Part: Clearance of Tisotumab Vedotin and Total HuMax-TF

    Pharmacokinetic (PK) parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not collected to report or calculate clearance for the expansion phase.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  8. Dose Escalation Part: Volume of Distribution of Tisotumab Vedotin and Total HuMax-TF

    PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not planned to be collected for the volume of distribution of tisotumab vedotin and total HuMax-TF for the dose expansion part.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  9. Dose Escalation and Expansion Part: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Tisotumab Vedotin and Total HuMax-TF

    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  10. Dose Escalation Part: Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tisotumab Vedotin and Total HuMax-TF

    PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was only analyzed in the dose escalation part of the study. Data was not planned to be collected for the AUC0-inf of tisotumab vedotin and total HuMax-TF for the dose expansion part.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  11. Dose Escalation and Expansion Part: Maximum Observed Plasma Concentration (Cmax) of Tisotumab Vedotin and Total HuMax-TF

    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  12. Dose Escalation and Expansion Part: Time of Cmax (Tmax) of Tisotumab Vedotin and Total HuMax-TF

    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  13. Dose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF

    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. t1/2 was only analyzed for the dose escalation part of the study. Data was not planned to be collected for t1/2 of tisotumab vedotin and total HuMax-TF for the dose expansion part.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  14. Dose Escalation and Expansion Part: AUC0-t of Free Monomethyl Auristatin E (MMAE)

    PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  15. Dose Escalation Part: AUC0-inf of Free MMAE

    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was not planned to be collected for the dose expansion part. AUC0-inf was not calculated where the percentage of the AUC that was due to the extrapolation was more than 20%.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  16. Dose Escalation and Expansion Part: Cmax of Free MMAE

    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  17. Dose Escalation and Expansion Part: Tmax of Free MMAE

    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  18. Dose Escalation Part: PK Parameters, T 1/2 of Free MMAE

    PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study.

    Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

  19. Dose Escalation and Expansion Part: Number of Participants With Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin

    Participants who met the criterion for positive ADAs on treatment were defined as participants who were negative at baseline and had at least one positive post-baseline result, or participants who were positive at baseline and had at least one post baseline result with a titer higher than baseline.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  20. Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage

    Anti-tumor activity measured by the number of participants who experienced tumor shrinkage was not planned to be collected for the dose expansion part.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  21. Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements

    Anti-tumor activity measured by maximum reduction among available post-baseline sum of lesion measurements was not planned to be collected for the dose escalation part.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  22. Dose Escalation and Expansion Part: Percentage Change From Baseline in Prostate Specific Antigen (PSA)

    PSA was only assessed in participants with castrate-resistant prostate cancer.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  23. Dose Escalation and Expansion Part: Percentage Change From Baseline in CA-125

    In the dose escalation part, CA-125 was only assessed for participants with ovarian cancer. In the dose expansion part, CA-125 was intended to be assessed only for participants with ovarian and endometrium cancer, but was additionally assessed for some participants with NSCLC and cervical cancer.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  24. Dose Escalation and Expansion Part: Objective Response Rate

    Objective Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Response assessment was investigator based for the escalation part and Independent Review Committee (IRC) based for the expansion part.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  25. Dose Escalation and Expansion Part: Disease Control Rate

    Disease control rate was defined as the percentage of participants with CR, PR or stable disease (SD) as per investigator assessment per RECIST version 1.1 after 6, 12, 24 and 36 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease.

    Time frame: At 6, 12, 24 and 36 weeks

  26. Dose Escalation and Expansion Part: Progression Free Survival (PFS)

    PFS was defined as the time in weeks from Day 1 in Cycle 1 to first disease progression or death, whichever occurred earliest, as assessed by the investigator. Only deaths that occurred within 60 days of the last visit were considered in the analysis and result are presented based on Kaplan-Meier estimates. Progression as defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase from nadir in the sum of diameters of target lesions, unequivocal progression in non-target lesions, or the appearance of new lesions

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

  27. Dose Expansion Part: Duration of Response (DOR)

    DOR was defined as the median time in weeks from when confirmed response was first documented until the first documented disease progression, or death from any cause, whichever was earliest as assessed by the investigator. A responder was defined as any participant with a best overall response of confirmed CR or PR.

    Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

07

Results

Posted Dec 29, 2021

Participant flow

Participant flow — Overall Study
MilestoneDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Started3333333615551415153618
Completed 4 cycles of treatment01120221531646227
Completed 12 cycles of treatment010100000300110
Completed000100000200110
Not completed3332333615531415143518
Withdrew: Disease progression22323233740599209
Withdrew: Physician decision000000003233121
Withdrew: Death010000000000000
Withdrew: Adverse event000001034640356
Withdrew: Other - miscellaneous000000000100010
Withdrew: Withdrawal by subject100000001322152
Withdrew: Lost to follow-up000000000100000
Withdrew: Start of new anti-cancer treatment000000000001010
Withdrew: Dose delay due to toxicity000000000000010

Outcome measures

PrimaryDose Escalation Part: Evaluation of Treatment-Emergent Adverse Events

Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame:
Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.
Reported as:
Count of participants · Participants
Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events
ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kg
TEAEs33333336
Serious TEAEs21022224
Infusion-Related TEAEs10000000
CTCAE Grade >=3 TEAEs23112324
TEAEs Related to Study Drug33233336
SecondaryDose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Hematology Values

Number of participants with markedly abnormal hematology values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 hematology value. A markedly abnormal hematology value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Count of participants · Participants
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Hematology Values
ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Hematology Values2110220102303153
SecondaryDose Escalation and Expansion Parts: Number of Participants With Markedly Abnormal Coagulation Values

Number of participants with markedly abnormal coagulation values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 coagulation value. A markedly abnormal coagulation value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Count of participants · Participants
Dose Escalation and Expansion Parts: Number of Participants With Markedly Abnormal Coagulation Values
ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Parts: Number of Participants With Markedly Abnormal Coagulation Values000000011720254
SecondaryDose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Biochemistry Values

Number of participants with markedly abnormal biochemistry results were defined as all participants who experienced at least 1 CTCAE grade \>= 3 biochemistry value. A markedly abnormal biochemistry value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Count of participants · Participants
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Biochemistry Values
ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Biochemistry Values213010124846294
SecondaryDose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash
Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Count of participants · Participants
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash
ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash100202243622285
SecondaryDose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event of Special Interest

Bleeding adverse events of special interest included treatment emergent adverse events with preferred terms within the following standardised MedDRA queries (SMQs): Haemorrhage terms, excluding laboratory terms SMQ \[20000039\] (Broad) and Haemorrhage, laboratory terms SMQ \[20000040\] (Narrow). Bleeding adverse events of special interest were evaluated according to the NCI-CTCAE version 4.03. Bleeding events of all grades are included. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Count of participants · Participants
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event of Special Interest
ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event of Special Interest01033325103110792710
SecondaryDose Escalation and Expansion Part: Number of Participants Who Experienced a Peripheral Neuropathy Event

Peripheral neuropathy events of special interest were evaluated according to the NCI-CTCAE version 4.03. Peripheral neuropathy events of all grades are included in the numbers below. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Count of participants · Participants
Dose Escalation and Expansion Part: Number of Participants Who Experienced a Peripheral Neuropathy Event
ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Part: Number of Participants Who Experienced a Peripheral Neuropathy Event01110101517635177
SecondaryDose Escalation Part: Clearance of Tisotumab Vedotin and Total HuMax-TF

Pharmacokinetic (PK) parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not collected to report or calculate clearance for the expansion phase.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · mL/hr/kg
Dose Escalation Part: Clearance of Tisotumab Vedotin and Total HuMax-TF
mL/hr/kgDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kg
Tisotumab Vedotin: Cycle 1—1.61 ± 7.791.46 ± 15.231.07 ± 11.601.84 ± 20.591.17 ± 60.051.56 ± 34.120.87 ± 8.93
Tisotumab Vedotin: Cycle 2—1.72 ± 4.981.44 ± 6.321.07 ± 10.452.05 ± 26.800.93 ± 24.031.30 ± 19.061.03 ± 11.34
Total HuMax-TF: Cycle 1—1.02 ± 0.200.98 ± 16.900.69 ± 12.611.26 ± 31.290.81 ± 69.720.87 ± 33.850.56 ± 14.13
Total HuMax-TF: Cycle 2—1.05 ± 9.950.98 ± 6.520.71 ± 13.411.40 ± 31.390.53 ± 12.410.82 ± 26.450.61 ± 9.72
SecondaryDose Escalation Part: Volume of Distribution of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not planned to be collected for the volume of distribution of tisotumab vedotin and total HuMax-TF for the dose expansion part.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · mL/kg
Dose Escalation Part: Volume of Distribution of Tisotumab Vedotin and Total HuMax-TF
mL/kgDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kg
Tisotumab Vedotin: Cycle 1—68.40 ± 11.8470.80 ± 14.5463.46 ± 16.8786.10 ± 12.3881.13 ± 35.6092.04 ± 21.6261.46 ± 18.07
Tisotumab Vedotin: Cycle 2—76.69 ± 9.5369.74 ± 7.9962.61 ± 6.0399.20 ± 20.8270.21 ± 42.9374.82 ± 4.1972.74 ± 5.79
Total HuMax-TF: Cycle 1—51.55 ± 1.6160.27 ± 17.7957.38 ± 8.6577.55 ± 10.7467.26 ± 50.6168.69 ± 30.5250.69 ± 7.20
Total HuMax-TF: Cycle 2—55.75 ± 10.8057.13 ± 8.9058.48 ± 12.6684.98 ± 22.8550.62 ± 36.0260.40 ± 17.4858.10 ± 12.31
SecondaryDose Escalation and Expansion Part: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · day*ug/mL
Dose Escalation and Expansion Part: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Tisotumab Vedotin and Total HuMax-TF
day*ug/mLDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Pharmacokinetics (PK) Analysis Set
Tisotumab Vedotin: Cycle 12.5 ± 3.115.4 ± 8.225.1 ± 16.945.2 ± 9.333.1 ± 19.063.0 ± 49.352.3 ± 33.184.9 ± 33.779.31 ± 49.40
Tisotumab Vedotin: Cycle 22.0 ± 15.79.9 ± 49.125.6 ± 7.145.2 ± 10.129.8 ± 25.142.7 ± 72.762.7 ± 21.586.3 ± 14.468.54 ± 55.49
Total HuMax-TF: Cycle 12.9 ± 0.515.4 ± 53.135.0 ± 18.960.4 ± 13.444.9 ± 27.886.7 ± 54.385.9 ± 36.7123.0 ± 34.7112.70 ± 45.23
Total HuMax-TF: Cycle 22.4 ± 12.314.4 ± 55.435.7 ± 7.158.8 ± 15.540.9 ± 26.260.2 ± 76.692.5 ± 33.4133.6 ± 13.9114.54 ± 45.83
SecondaryDose Escalation Part: Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was only analyzed in the dose escalation part of the study. Data was not planned to be collected for the AUC0-inf of tisotumab vedotin and total HuMax-TF for the dose expansion part.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · day*ug/mL
Dose Escalation Part: Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tisotumab Vedotin and Total HuMax-TF
day*ug/mLDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kg
Tisotumab Vedotin: Cycle 1—15.57 ± 7.8125.77 ± 15.7046.68 ± 10.9933.95 ± 20.9363.88 ± 48.6153.47 ± 30.88105.84 ± 8.68
Tisotumab Vedotin: Cycle 2—14.52 ± 4.9826.12 ± 6.4446.59 ± 9.9830.56 ± 26.4380.59 ± 24.0364.10 ± 19.0688.95 ± 11.04
Total HuMax-TF: Cycle 1—23.75 ± 0.2037.02 ± 16.3969.96 ± 13.2648.19 ± 35.6790.08 ± 52.7493.29 ± 30.45157.81 ± 12.70
Total HuMax-TF: Cycle 2—23.01 ± 9.9537.08 ± 6.3767.93 ± 14.2543.41 ± 30.31136.08 ± 12.4198.59 ± 26.45145.82 ± 9.42
SecondaryDose Escalation and Expansion Part: Maximum Observed Plasma Concentration (Cmax) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · ug/mL
Dose Escalation and Expansion Part: Maximum Observed Plasma Concentration (Cmax) of Tisotumab Vedotin and Total HuMax-TF
ug/mLDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Pharmacokinetics (PK) Analysis Set
Tisotumab Vedotin: Cycle 14.78 ± 12.3512.20 ± 9.4719.81 ± 17.3234.67 ± 18.4823.12 ± 21.1035.42 ± 39.2032.30 ± 22.0855.53 ± 10.3129.1 ± 34.1
Tisotumab Vedotin: Cycle 23.85 ± 27.6512.51 ± 11.5120.25 ± 5.1432.38 ± 7.1121.84 ± 24.9735.92 ± 30.3944.30 ± 0.3248.79 ± 26.3726.1 ± 41.2
Total HuMax-TF: Cycle 14.90 ± 13.0011.84 ± 8.3117.98 ± 11.6429.30 ± 10.1423.55 ± 25.1630.57 ± 37.4238.78 ± 21.7758.02 ± 12.7739.8 ± 31.1
Total HuMax-TF: Cycle 23.96 ± 21.8311.54 ± 8.8316.90 ± 1.5731.33 ± 8.1322.11 ± 21.0337.71 ± 42.9643.40 ± 6.6753.67 ± 19.7538.3 ± 33.3
SecondaryDose Escalation and Expansion Part: Time of Cmax (Tmax) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · hours
Dose Escalation and Expansion Part: Time of Cmax (Tmax) of Tisotumab Vedotin and Total HuMax-TF
hoursDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Pharmacokinetics (PK) Analysis Set
Tisotumab Vedotin: Cycle 11.47 ± 72.741.18 ± 13.031.34 ± 11.771.15 ± 11.661.12 ± 9.551.18 ± 14.301.18 ± 7.451.11 ± 12.521.21 ± 364.12
Tisotumab Vedotin: Cycle 21.54 ± 63.291.34 ± 6.271.32 ± 5.961.13 ± 11.181.21 ± 16.612.44 ± 35.751.14 ± 9.291.29 ± 7.551.44 ± 303.89
Total HuMax-TF: Cycle 12.20 ± 49.151.18 ± 13.031.34 ± 11.771.15 ± 11.661.12 ± 9.551.18 ± 14.301.18 ± 7.451.11 ± 12.521.10 ± 397.92
Total HuMax-TF: Cycle 22.19 ± 46.561.34 ± 6.271.32 ± 5.961.13 ± 11.181.21 ± 16.611.76 ± 50.431.14 ± 9.291.29 ± 7.551.15 ± 356.23
SecondaryDose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. t1/2 was only analyzed for the dose escalation part of the study. Data was not planned to be collected for t1/2 of tisotumab vedotin and total HuMax-TF for the dose expansion part.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · hours
Dose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF
hoursDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kg
Tisotumab Vedotin: Cycle 112.22 ± 11.6129.53 ± 4.0833.72 ± 6.2641.06 ± 6.8532.42 ± 20.0547.89 ± 25.8240.93 ± 11.4841.19 ± 34.02
Tisotumab Vedotin: Cycle 213.54 ± 5.5023.50 ± 39.8933.68 ± 1.7440.44 ± 4.6933.62 ± 14.5032.15 ± 62.7439.89 ± 23.1548.93 ± 5.61
Total HuMax-TF: Cycle 116.05 ± 27.9328.66 ± 30.6442.52 ± 7.4857.37 ± 8.6542.72 ± 34.6257.72 ± 17.4754.95 ± 5.3255.10 ± 27.36
Total HuMax-TF: Cycle 218.34 ± 8.7330.71 ± 27.6540.37 ± 4.2756.77 ± 9.6042.18 ± 25.3946.24 ± 53.1151.06 ± 9.1866.05 ± 10.07
SecondaryDose Escalation and Expansion Part: AUC0-t of Free Monomethyl Auristatin E (MMAE)

PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · day*ng/mL
Dose Escalation and Expansion Part: AUC0-t of Free Monomethyl Auristatin E (MMAE)
day*ng/mLDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Pharmacokinetics (PK) Analysis Set
Cycle 16.20 ± 72.0512.61 ± 28.1812.22 ± 67.2311.63 ± 52.6926.55 ± 44.2422.55 ± 57.2667.42 ± 59.9826.47 ± 59.3525.80 ± 93.91
Cycle 23.19 ± 140.854.69 ± 87.2714.89 ± 66.9716.92 ± 58.1221.51 ± 34.2518.97 ± 52.1436.20 ± 33.8237.50 ± 43.0823.48 ± 76.47
SecondaryDose Escalation Part: AUC0-inf of Free MMAE

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was not planned to be collected for the dose expansion part. AUC0-inf was not calculated where the percentage of the AUC that was due to the extrapolation was more than 20%.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · day*ng/mL
Dose Escalation Part: AUC0-inf of Free MMAE
day*ng/mLDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kg
Cycle 112.63 ± 12.4413.93 ± NA16.32 ± 57.5620.39 ± NA27.08 ± 58.9625.29 ± NA78.31 ± NA63.03 ± NA
Cycle 2——22.32 ± 43.6231.40 ± NA31.43 ± NA33.23 ± NA—58.95 ± NA
SecondaryDose Escalation and Expansion Part: Cmax of Free MMAE

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · ng/mL
Dose Escalation and Expansion Part: Cmax of Free MMAE
ng/mLDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Pharmacokinetics (PK) Analysis Set
Cycle 10.760 ± 62.5051.673 ± 30.7561.524 ± 54.4911.410 ± 19.1492.807 ± 39.3982.587 ± 29.1726.351 ± 61.5054.877 ± 31.3503.16 ± 88.30
Cycle 21.091 ± 74.2931.342 ± 24.3202.059 ± 51.4702.243 ± 50.3672.718 ± 39.4922.035 ± 39.7853.369 ± 36.8754.704 ± 18.8562.73 ± 78.69
SecondaryDose Escalation and Expansion Part: Tmax of Free MMAE

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · hours
Dose Escalation and Expansion Part: Tmax of Free MMAE
hoursDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Pharmacokinetics (PK) Analysis Set
Cycle 123.88 ± 4.4122.77 ± 16.5624.39 ± 7.7224.19 ± 5.5225.07 ± 0.6847.74 ± 114.2883.24 ± 67.5784.88 ± 61.54154.28 ± 54.214
Cycle 223.73 ± 5.7824.05 ± 8.4823.92 ± 13.0424.94 ± 1.4825.26 ± 0.7646.24 ± 112.4865.15 ± 104.6147.12 ± 112.10125.38 ± 31.21
SecondaryDose Escalation Part: PK Parameters, T 1/2 of Free MMAE

PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study.

Time frame:
Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Reported as:
Geometric mean · hours
Dose Escalation Part: PK Parameters, T 1/2 of Free MMAE
hoursDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kg
Cycle 195.15 ± 25.7469.34 ± NA63.98 ± 2.2462.58 ± NA63.65 ± 7.8678.90 ± NA57.74 ± NA68.47 ± NA
Cycle 2——69.65 ± 3.8660.71 ± NA70.20 ± NA78.94 ± NA—63.92 ± NA
SecondaryDose Escalation and Expansion Part: Number of Participants With Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin

Participants who met the criterion for positive ADAs on treatment were defined as participants who were negative at baseline and had at least one positive post-baseline result, or participants who were positive at baseline and had at least one post baseline result with a titer higher than baseline.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Count of participants · Participants
Dose Escalation and Expansion Part: Number of Participants With Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin
ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Part: Number of Participants With Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin000000001300101
SecondaryDose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage

Anti-tumor activity measured by the number of participants who experienced tumor shrinkage was not planned to be collected for the dose expansion part.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Count of participants · Participants
Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage
ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kg
Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage00010213
PrimaryDose Expansion Part: Evaluation of Treatment-Emergent Adverse Events

Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame:
Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.
Reported as:
Count of participants · Participants
Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events
ParticipantsDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
TEAEs15551415153618
Serious TEAEs726586136
Infusion-Related TEAEs1111200
CTCAE Grade >=3 TEAEs93088101611
TEAEs Related to Study Drug15541314143618
SecondaryDose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements

Anti-tumor activity measured by maximum reduction among available post-baseline sum of lesion measurements was not planned to be collected for the dose escalation part.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Median · millimeter(s)
Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements
millimeter(s)Dose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements6.00 (-127.0 to 41.0)-8.50 (-64.0 to 50.0)1.00 (-11.0 to 26.0)-2.00 (-51.0 to 40.0)0.00 (-59.0 to 31.0)-4.00 (-41.0 to 115.0)-1.00 (-11.0 to 15.0)
SecondaryDose Escalation and Expansion Part: Percentage Change From Baseline in Prostate Specific Antigen (PSA)

PSA was only assessed in participants with castrate-resistant prostate cancer.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Median · Percentage Change in PSA
Dose Escalation and Expansion Part: Percentage Change From Baseline in Prostate Specific Antigen (PSA)
Percentage Change in PSADose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Part: Percentage Change From Baseline in Prostate Specific Antigen (PSA)—64.35 (64.35 to 64.35)—40.91 (40.91 to 40.91)3.92 (3.92 to 3.92)———60.07 (3.4 to 996.5)
SecondaryDose Escalation and Expansion Part: Percentage Change From Baseline in CA-125

In the dose escalation part, CA-125 was only assessed for participants with ovarian cancer. In the dose expansion part, CA-125 was intended to be assessed only for participants with ovarian and endometrium cancer, but was additionally assessed for some participants with NSCLC and cervical cancer.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Median · Percentage Change
Dose Escalation and Expansion Part: Percentage Change From Baseline in CA-125
Percentage ChangeDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian Cancer
Dose Escalation and Expansion Part: Percentage Change From Baseline in CA-125———18.75 (18.75 to 18.75)—-13.98 (-13.98 to -13.98)113.71 (113.71 to 113.71)11.62 (-22.7 to 45.9)-25.17 (-88.7 to 240.5)37.85 (-46.1 to 666.2)180.94 (47.1 to 980.5)73.19 (-89.0 to 1924.4)
SecondaryDose Escalation and Expansion Part: Objective Response Rate

Objective Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Response assessment was investigator based for the escalation part and Independent Review Committee (IRC) based for the expansion part.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Number · Percentage of Participants
Dose Escalation and Expansion Part: Objective Response Rate
Percentage of ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Part: Objective Response Rate0 (0 to 71)0 (0 to 71)0 (0 to 71)33 (1 to 91)0 (0 to 71)0 (0 to 71)0 (0 to 71)0 (0 to 46)27 (8 to 55)24 (13 to 37)7 (0 to 34)13 (2 to 40)13 (2 to 40)14 (5 to 29)0 (0 to 19)
SecondaryDose Escalation and Expansion Part: Disease Control Rate

Disease control rate was defined as the percentage of participants with CR, PR or stable disease (SD) as per investigator assessment per RECIST version 1.1 after 6, 12, 24 and 36 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease.

Time frame:
At 6, 12, 24 and 36 weeks
Reported as:
Number · Percentage of Participants
Dose Escalation and Expansion Part: Disease Control Rate
Percentage of ParticipantsDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Week 60 (0 to 71)33 (1 to 91)33 (1 to 91)67 (9 to 99)33 (1 to 91)100 (29 to 100)67 (9 to 99)50 (12 to 88)47 (21 to 73)60 (46 to 73)64 (35 to 87)40 (16 to 68)60 (32 to 84)72 (55 to 86)61 (36 to 83)
Week 120 (0 to 71)33 (1 to 91)33 (1 to 91)67 (9 to 99)0 (0 to 71)67 (9 to 99)33 (1 to 91)0 (0 to 46)33 (12 to 62)47 (34 to 61)43 (18 to 71)20 (4 to 48)13 (2 to 40)42 (26 to 59)28 (10 to 53)
Week 240 (0 to 71)33 (1 to 91)0 (0 to 71)33 (1 to 91)0 (0 to 71)0 (0 to 71)0 (0 to 71)0 (0 to 46)20 (4 to 48)18 (9 to 31)21 (5 to 51)7 (0 to 32)13 (2 to 40)14 (5 to 29)6 (0 to 27)
Week 360 (0 to 71)33 (1 to 91)0 (0 to 71)33 (1 to 91)0 (0 to 71)0 (0 to 71)0 (0 to 71)0 (0 to 46)7 (0 to 32)11 (4 to 22)0 (0 to 23)0 (0 to 22)7 (0 to 32)3 (0 to 15)6 (0 to 27)
SecondaryDose Escalation and Expansion Part: Progression Free Survival (PFS)

PFS was defined as the time in weeks from Day 1 in Cycle 1 to first disease progression or death, whichever occurred earliest, as assessed by the investigator. Only deaths that occurred within 60 days of the last visit were considered in the analysis and result are presented based on Kaplan-Meier estimates. Progression as defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase from nadir in the sum of diameters of target lesions, unequivocal progression in non-target lesions, or the appearance of new lesions

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Median · Weeks
Dose Escalation and Expansion Part: Progression Free Survival (PFS)
WeeksDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Escalation and Expansion Part: Progression Free Survival (PFS)5.1 (4.9 to 5.4)6.0 (3.9 to 49.1)6.1 (4.9 to NA)27.1 (6.0 to NA)6.1 (5.3 to 10.4)17.1 (11.3 to NA)12.3 (5.0 to 14.1)11.3 (2.1 to 11.3)11.0 (5.1 to 43.0)18.1 (9.3 to 23.0)NA (5.1 to NA)10.1 (5.3 to 17.0)13.0 (5.1 to 17.3)13.0 (12.1 to 18.3)12.9 (7.1 to 23.7)
SecondaryDose Expansion Part: Duration of Response (DOR)

DOR was defined as the median time in weeks from when confirmed response was first documented until the first documented disease progression, or death from any cause, whichever was earliest as assessed by the investigator. A responder was defined as any participant with a best overall response of confirmed CR or PR.

Time frame:
Day 1 to end of follow-up, up to a maximum of 60 weeks
Reported as:
Median · Weeks
Dose Expansion Part: Duration of Response (DOR)
WeeksDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Dose Expansion Part: Duration of Response (DOR)———NA (NA to NA)————32.0 (11.0 to 32.0)18.4 (13.1 to 41.7)NA (NA to NA)18.3 (11.6 to 25.0)NA (12.0 to NA)21.4 (13.1 to 29.6)—

Adverse events

Collected over Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the escalation part and from 1 to 325 days in the expansion part.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation Part: 0.3 mg/kg2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Dose Escalation Part: 0.6 mg/kg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Dose Escalation Part: 0.9 mg/kg0/3 (0%)0/3 (0%)3/3 (100%)
Dose Escalation Part: 1.2 mg/kg0/3 (0%)2/3 (66.7%)3/3 (100%)
Dose Escalation Part: 1.5 mg/kg0/3 (0%)2/3 (66.7%)3/3 (100%)
Dose Escalation Part: 1.8 mg/kg0/3 (0%)2/3 (66.7%)3/3 (100%)
Dose Escalation Part: 2.0 mg/kg0/3 (0%)2/3 (66.7%)3/3 (100%)
Dose Escalation Part: 2.2 mg/kg0/6 (0%)4/6 (66.7%)6/6 (100%)
Dose Expansion Part: Bladder Cancer0/15 (0%)7/15 (46.7%)15/15 (100%)
Dose Expansion Part: Cervical Cancer2/55 (3.6%)26/55 (47.3%)55/55 (100%)
Dose Expansion Part: Endometrial Cancer0/14 (0%)5/14 (35.7%)14/14 (100%)
Dose Expansion Part: Esophageal Cancer1/15 (6.7%)8/15 (53.3%)15/15 (100%)
Dose Expansion Part: Non-Small-Cell Lung Cancer1/15 (6.7%)6/15 (40%)15/15 (100%)
Dose Expansion Part: Ovarian Cancer2/36 (5.6%)13/36 (36.1%)36/36 (100%)
Dose Expansion Part: Prostate Cancer1/18 (5.6%)6/18 (33.3%)18/18 (100%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small-Cell Lung CancerDose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/30/30/30/30/30/30/30/60/152/550/140/150/150/360/18
Abdominal painGastrointestinal disorders0/30/30/31/31/30/30/32/60/152/550/140/150/152/361/18
Small intestinal obstructionGastrointestinal disorders0/30/30/31/30/30/30/30/60/150/550/140/150/151/360/18
Intestinal obstructionGastrointestinal disorders0/30/30/31/30/30/31/30/60/150/550/140/150/150/360/18
AscitesGastrointestinal disorders1/30/30/30/30/30/30/30/60/150/550/140/150/150/360/18
GastritisGastrointestinal disorders0/30/30/30/30/31/30/30/60/150/550/140/150/150/360/18
Cystitis escherichiaInfections and infestations1/30/30/30/30/30/30/30/60/150/550/140/150/150/360/18
Klebsiella infectionInfections and infestations0/30/30/30/31/30/30/30/60/150/550/140/150/150/360/18
PyrexiaGeneral disorders0/30/30/31/30/30/30/30/60/152/550/141/150/150/360/18
General physical health deteriorationGeneral disorders0/30/30/30/30/30/31/30/60/150/550/141/150/151/360/18
Most frequent other events
Showing 10 of 293
Most frequent other events
EventDose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small-Cell Lung CancerDose Expansion Part: Ovarian CancerDose Expansion Part: Prostate Cancer
EpistaxisRespiratory, thoracic and mediastinal disorders0/30/30/33/32/33/32/34/613/1528/5511/148/1511/1530/3612/18
FatigueGeneral disorders3/31/31/31/30/33/30/34/68/1529/5510/1410/158/1515/3615/18
AnaemiaBlood and lymphatic system disorders0/33/31/32/30/31/31/33/61/1513/552/143/152/150/363/18
Decreased appetiteMetabolism and nutrition disorders1/30/30/30/30/30/31/35/63/1520/555/146/155/1512/3610/18
NauseaGastrointestinal disorders1/30/31/31/30/31/31/34/67/1525/557/147/1510/1520/3612/18
ConstipationGastrointestinal disorders2/30/30/30/31/32/31/33/66/1519/553/146/155/1511/369/18
DiarrhoeaGastrointestinal disorders2/31/30/31/30/30/32/30/63/1517/556/142/154/1514/365/18
StomatitisGastrointestinal disorders0/30/32/30/30/30/31/30/61/150/551/140/150/156/362/18
Nasal congestionRespiratory, thoracic and mediastinal disorders0/30/30/32/31/31/30/30/60/155/551/140/151/154/360/18
PyrexiaGeneral disorders2/30/31/31/30/30/30/34/62/1511/551/142/150/154/360/18

Baseline characteristics

Full analysis set: all participants who had been exposed to tisotumab vedotin in either the dose escalation or expansion parts.

Age, Customized
Age, Customized(Participants)Dose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate CancerTotal
In utero0000000000000000
Preterm newborn infants (gestational age < 37 wks)0000000000000000
Newborns (0-27 days)0000000000000000
Infants and toddlers (28 days-23 months)0000000000000000
Children (2-11 years)0000000000000000
Adolescents (12-17 years)0000000000000000
Adults (18-64 years)313322241251889264138
From 65-84 years0200111234676101457
85 years and over0000000000000000
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate CancerTotal
Female1112233525514312360140
Male22211001130012301855
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate CancerTotal
Hispanic or Latino0000000000100102
Not Hispanic or Latino3333333615531315153518191
Unknown or Not Reported0000000002000002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation Part: 0.3 mg/kgDose Escalation Part: 0.6 mg/kgDose Escalation Part: 0.9 mg/kgDose Escalation Part: 1.2 mg/kgDose Escalation Part: 1.5 mg/kgDose Escalation Part: 1.8 mg/kgDose Escalation Part: 2.0 mg/kgDose Escalation Part: 2.2 mg/kgDose Expansion Part: Bladder CancerDose Expansion Part: Cervical CancerDose Expansion Part: Endometrial CancerDose Expansion Part: Esophageal CancerDose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)Dose Expansion Part: Ovarian CancerDose Expansion Part: Prostate CancerTotal
White3333333615491413133417182
Black or Asian American0000000001000012
Asian0000000003011005
American Indian or Alaska Native0000000000000000
Native Hawaiian or other Pacific Islander0000000000001001
Other0000000000010102
Missing0000000002000103
08

Study locations

29 sites
  • University of California Irvine Medical Center (UCIMC)
    Orange, California 92868-3201, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • University of Miami
    Miami, Florida 33136, United States
  • University Gynecologic Oncology
    Atlanta, Georgia 30342, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Universitair Ziekenhuis Antwerpen
    Edegem, Antwerpen 2650, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, Flemish Brabant 3000, Belgium
  • Grand Hôpital de Charleroi
    Charleroi, Hainaut 6000, Belgium
  • Centre Hospitalier Universitaire Ambroise Paré
    Mons, Hainaut 7000, Belgium
  • CHU UCL Namur - site Godinne
    Yvoir, Namur 5530, Belgium
  • Saint-Luc University Hospital
    Brussels, 1200, Belgium
  • CHU de Liège
    Liège, 4000, Belgium
  • CHU UCL Namur - Sainte Elisabeth
    Namur, 5000, Belgium
  • Rigshospitalet, Copenhagen University Hospital
    Copenhagen, DK-2100, Denmark
  • Herlev and Gentofte Hospital
    Herlev, 2730, Denmark
  • Karolinska Universitetssjukhuset
    Stockholm, Solna 17176, Sweden
  • Lungemedicinska Kliniken
    Linköping, 58185, Sweden
  • The Leeds Teaching Hospitals NHS Trust
    Leeds, England LS9 7TF, United Kingdom
  • University College London Hospitals
    London, England NW1 2BU, United Kingdom
  • Sarah Cannon Research Institute - London
    London, England W1G 6AD, United Kingdom
  • Newcastle Hospitals NHS Foundation Trust
    Newcastle upon Tyne, Newcastle NE7 7DN, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    Sutton, Surrey SM2 5PT, United Kingdom
  • Velindre NHS Trust
    Cardiff, Wales CF14 2TL, United Kingdom
  • Beatson Cancer Centre
    Glasgow, G12 OYN, United Kingdom
  • Guys hospital
    London, SE1 9RT, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sorensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Mar;20(3):383-393. doi: 10.1016/S1470-2045(18)30859-3. Epub 2019 Feb 8. Erratum In: Lancet Oncol. 2019 Dec;20(12):e663. doi: 10.1016/S1470-2045(19)30753-3. PubMed 30745090 ↗
  • Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Cancer Res. 2020 Mar 15;26(6):1220-1228. doi: 10.1158/1078-0432.CCR-19-2962. Epub 2019 Dec 3. PubMed 31796521 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in May 2019, 65 months.

Results were first posted in Dec 2021, 2 years 7 months after primary completion. A results delay was requested in Apr 2020.

Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's 65 months is close to that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2013
First posted
Dec 5, 2013
StartActual
Nov 30, 2013
Primary completionActual
May 2, 2019
CompletionActual
May 2, 2019
Results delay requested
Apr 21, 2020
Results first posted
Dec 29, 2021
Last update
Dec 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02001623
Lead sponsor
Seagen Inc.
Collaborators
Genmab
Responsible party
Sponsor
First posted
Dec 5, 2013
Start date
Nov 30, 2013
Primary completion
May 2, 2019
Completion
May 2, 2019
Results posted
Dec 29, 2021
Last update
Dec 29, 2021

Study contacts

Johann de Bono, Professor
principal investigator · The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisotumab vedotin

Start the discussion